Abstract: The method includes receiving digital images of tissue samples of patients, the images having assigned a label indicating a patient-related attribute value; splitting each received image into a set of image tiles; computing a feature vector for each tile; training a Multiple-Instance-Learning program on all the tiles and respective feature vectors for computing for each of the tiles a numerical value being indicative of the predictive power of the feature vector associated with the tile in respect to the label of the tile's respective image; and outputting a report gallery including tiles sorted in accordance with their respectively computed numerical value and/or including a graphical representation of the numerical value.
Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that is greater than or equal to 12 years of age and less than 18 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody.
Type:
Application
Filed:
September 12, 2023
Publication date:
February 8, 2024
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
Type:
Application
Filed:
September 8, 2023
Publication date:
February 8, 2024
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Type:
Application
Filed:
December 16, 2022
Publication date:
February 8, 2024
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.
Abstract: Herein is reported a method for producing a thymocyte supernatant comprising the steps of co-cultivating thymocytes and mononuclear cells at a cell ratio of at least 0.5:1.2 in the presence of phorbol-12-myristate-13-acetate and Phytohemagglutinin M for up to 60 hours, and separating the co-cultivation medium from the cells and thereby producing the thymocyte supernatant.
Type:
Grant
Filed:
October 2, 2019
Date of Patent:
February 6, 2024
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Sonja Offner, Markus Horvath, Ingried Saam
Abstract: Herein is reported a method for the final filtration of concentrated polypeptide solutions comprising the combination of two immediately consecutive filtration steps with a first filter of 3.0 ?m and 0.8 ?m pore size and a second filter of 0.45 ?m and 0.22 ?m pore size.
Abstract: Processes are provided herein for the preparation of a bicyclic ketone compound of formula (I), or a stereoisomer thereof: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and n are as defined herein; and compounds prepared by these processes.
Type:
Application
Filed:
October 2, 2023
Publication date:
February 1, 2024
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Allen Yu HONG, Nicholas WONG, Sean M. KELLY, Lauren Elizabeth SIROIS, Sara SCHWEGLER, Xin LINGHU, Francis GOSSELIN, Katarzyna Aleksandra PIECHOWICZ, Carmela MOLINARO, Dennis WETZL
Abstract: The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.
Abstract: In some embodiments, a current state of a medical condition or a progression of the medical condition is predicted by processing one or more digital pathology images and expression levels of genes using a machine-learning model. In some embodiments, one or more predicted gene-expression levels are generated by processing a data set corresponding to one or more digital pathology images using a machine-learning model. In some embodiments, one or more predicted digital pathology metrics are generated by processing a data set that corresponds to expression levels of a set of genes using a machine-learning model.
Type:
Application
Filed:
August 14, 2023
Publication date:
February 1, 2024
Applicants:
GENENTECH, INC., HOFFMANN-LA ROCHE INC.
Abstract: Compounds having the general formula I wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds for treatment of GPR17-mediated diseases.
Type:
Application
Filed:
August 24, 2023
Publication date:
January 25, 2024
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Guido GALLEY, Luca GOBBI, Wolfgang GUBA, Dmitry MAZUNIN, Emmanuel PINARD, Antonio RICCI
Abstract: The present invention relates to a process for the preparation of a compound (I), (I); or pharmaceutically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and treatment of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
Abstract: The present invention generally relates to antibodies that bind to CD3 and PLAP, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
Type:
Application
Filed:
December 8, 2022
Publication date:
January 18, 2024
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Ali Bransi, Alejandro Carpy Gutierrez Cirlos, Anne Freimoser-Grundschober, Kerstin Hofer, Thomas Hofer, Tommy Kuehnl, Ekkehard Moessner, Christiane Neumann
Abstract: The invention relates to a compound of formula (I) wherein R1—R4 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
Abstract: Herein is reported a method for determining antibody-FcRn-interaction comprising the steps of immobilizing FcRn on a solid surface, which is suitable for surface plasmon resonance measurement, individually applying to the solid surface obtained in step a) solutions comprising the antibody at different concentrations and determining the association rate constant and the dissociation rate constant for each concentration, and determining with the rates obtained in step b) the KD-value of the antibody-FcRn-interaction, wherein the immobilized FcRn is monomeric FcRn, the monomeric FcRn is immobilized using functional (capture) groups that are directly attached to said solid surface, the solid surface is free of branched glucan, and the immobilization is at a pH value of from pH 7 to pH 8.
Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R4 and A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
Type:
Application
Filed:
November 29, 2021
Publication date:
January 18, 2024
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Christa Ulrike OBST-SANDER, Antonio RICCI
Abstract: The present invention relates to a process for the preparation of a compound (I), and its solid form, which is a modulator of ?-secretase and may be useful for prophylaxis and treatment of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
Abstract: The invention comprises a process for the preparation of a chiral triol of formula I wherein, R1 is hydrogen or halogen by way of an asymmetric hydrogenation of a ketone compound of formula IIa wherein, R1 is hydrogen or halogen and R2 is C1-6-alkyl; with hydrogen in the presence of an iridium spiro-pyridylamidophosphine catalyst (Ir-SpiroPAP catalyst). The chiral triols of formula I are versatile building blocks for the preparation of various pharmaceutically active drug substances such as for instance for statins.
Type:
Application
Filed:
July 12, 2023
Publication date:
January 18, 2024
Applicants:
Hoffmann-La Roche Inc., Genentech, Inc.
Inventors:
Anna-Lena GLASS, Allen Yu HONG, Kurt PUENTENER
Abstract: The present invention relates to novel solid forms of compound (I), 3-[(8aS)-7-[[(4S)-5-ethoxycarbonyl-4-(3-fluoro-2-methyl-phenyl)-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-2,2-dimethyl-propanoic acid and pharmaceutical compositions comprising solid forms thereof disclosed herein, which can be used as a HBV capsid inhibitor (or HBV Core Protein Allosteric Modifier), or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.